Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323052 | 1.00 | BCL2 (0.46) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL31058008 | 0.92 | BCL2 (0.43) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL30415477 | 0.89 | BCL2 (0.55) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL23323413 | 0.89 | BCL2 (0.55) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL31697992 | 0.88 | BCL2 (0.45) | BCL2BCL2L1 | |
| SCHEMBL24854062 | 0.86 | BCL2 (0.44) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL30154391 | 0.85 | BCL2A1 (0.44) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL1702063 | 0.85 | BCL2 (0.50) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL19867786 | 0.85 | BCL2 (0.50) | BCL2BCL2L1BCL2A1 | |
| SCHEMBL28839728 | 0.83 | BCL2 (0.51) | BCL2BCL2L1BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161279-A1 | METHODS OF TREATING MULTIPLE MYELOMA USING BCL-2 INHIBITOR | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-22 | — | — | US | disclosed |
| EP-4522169-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BeiGene Switzerland GmbH (CH) | 2025-03-19 | — | — | EP | disclosed |
| CN-114929689-B | Bcl-2 inhibitors | 百济神州有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023218410-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161279-A1 | METHODS OF TREATING MULTIPLE MYELOMA USING BCL-2 INHIBITOR | BCL3, MCL1, BCL6 | BCL2 4/4885BCL2L1 7/4885BCL2A1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.